Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer's heart failure drug Inspra (eplerenone) has been a spectacular commercial flop since it officially launched in 2004, but the drug could have renewed potential based on the results of new outcomes data. Pfizer announced May 27 that it is halting recruitment in an outcomes trial evaluating Inspra in a broader patient population early due to positive efficacy
You may also be interested in...
Heart failure drug's safety profile should become more clear – if the two-indication program hits the mark on dose selection and the evolving standard of care.
Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.
Pfizer is beginning its launch of the congestive heart failure therapy Inspra